Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Current Liabilities: 2020-2024

Historic Total Current Liabilities for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $185.5 million.

  • Apellis Pharmaceuticals' Total Current Liabilities rose 46.15% to $279.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $279.5 million, marking a year-over-year increase of 46.15%. This contributed to the annual value of $185.5 million for FY2024, which is 25.08% down from last year.
  • As of FY2024, Apellis Pharmaceuticals' Total Current Liabilities stood at $185.5 million, which was down 25.08% from $247.6 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Total Current Liabilities ranged from a high of $247.6 million in FY2023 and a low of $128.3 million during FY2020.
  • In the last 3 years, Apellis Pharmaceuticals' Total Current Liabilities had a median value of $185.5 million in 2024 and averaged $200.2 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 47.72% in 2023, then fell by 25.08% in 2024.
  • Apellis Pharmaceuticals' Total Current Liabilities (Yearly) stood at $128.3 million in 2020, then grew by 2.74% to $131.8 million in 2021, then grew by 27.12% to $167.6 million in 2022, then skyrocketed by 47.72% to $247.6 million in 2023, then declined by 25.08% to $185.5 million in 2024.